When megatrends collide, lives could be saved

Published 22 January 2024

Christopher Gannatti, CFA
Global Head of Research

Superconvergence. That's the big story of the moment, according to WisdomTree BioRevolution UCITS ETF partner, Jamie Metzl. Technologies of Artificial Intelligence (AI), genetics, and biotechnology revolutions are both inspiring and being inspired by one other, continuously accelerating innovation and impact. An impact that is being seen in many different sectors, including healthcare.

On 14 December 2023, Moderna reported data from an ongoing, early-stage, trial for a personalised therapy for late-stage melanoma, an often deadly type of skin cancer. Moderna's CEO, Stephane Bancel, described the approach and results during an interview with CNBC1:

- Cancer cells are typically subject to mutations within the patient's DNA, which could create the conditions for cancer to flourish.
- Moderna is able to use AI analytics and massive cloud computing power to analyse the sequenced DNA data derived from both cancerous cells and that of the healthy cells around them.
- Moderna's algorithm compares the cancerous DNA code to the healthy DNA code to help scientists understand how the cancer cells are mutating.
- This information is then used to identify unique elements of the cancer cells that could become targets for a patient's immune system.
- A therapy designed to trigger the individual patient's own immune system to attack the specific target in the cancer cells can then be created and delivered using the same mRNA technology that underpinned the COVID-19 vaccines, essentially training the patient's individual immune system to attack the unique cancer. Creating a personalised cancer vaccine.
- Remarkably, this personalised cancer therapy can be ready for use just 30 days after the patient's cells are extracted and sequenced, thanks to the combined tools of the AI, genetics, and biotechnology revolutions.

Moderna reported that after three years of trials, this therapy – mRNA-4157 – in combination with Merck's blockbuster cancer drug, Keytruda, reduced the risk of recurrence or death by 49% in late-stage melanoma patients compared with Keytruda alone. The combination reduced the risk of developing distant metastasis or death by 62%, compared with Keytruda alone2. These results are nothing short of astounding.

It sounds like science fiction, but discoveries like this are the future of many fields, including medicine, agriculture, materials science and data storage.

Biorevolution->AI->Cloud Computing

Moderna is pivoting from its COVID-19 mRNA vaccine development success to becoming a platform company upon which mRNA therapies can be used to achieve multiple goals.

Its cloud service provider, Amazon Web Services, is the world's largest public cloud platform, with roughly 40% of the market share. A unique value of these platforms is that a company like Moderna can never buy, on its own, the most advanced computational infrastructure that would allow for individual patient genomes to be analysed with the depth, speed, and scale that is possible through its partnership with AWS. Working with AWS provides Moderna with a suite of AI and machine learning tools to better process data, derive actionable insight and target capabilities.

So, we are seeing something that represents the intersection of three megatrends: biorevolution, AI and cloud computing. Many believe that the future of medicine will see us going from generic treatments – like everyone taking the same painkiller for a headache – to personalised medicine, recognising that each person is unique and can be treated differently. At the center of that transition is data, and when data is involved, you usually see the cloud and AI in the background.

Conclusion: Biotech for 2024

We have already written about biotechnology as an area that has experienced extreme underperformance of late. However, recently we've been seeing a lot of articles focused on falling interest rates which, historically, has been an indicator of positive returns in biotechnology.

While we think the macroeconomic dynamic is important, it's also important to recognise that science is advancing at an astounding rate. Even if there are ups and downs in some of the markets, the exponential growth of the capabilities driving massive societal change is undeniable. We recently wrote about Casgevy, a new CRISPR therapy for Sickle-Cell anemia3, and we now have an mRNA example too. We are excited that a more positive macro environment may coincide with improvements in AI and cloud computing, to support the efforts to make these therapies available for widespread use. Given that there are thousands of such therapies in the approval pipeline, with Moderna itself currently developing 40 different therapies – seven of which are in late-stage trials, the chance of this progress is likely4.

To capitalise on these trends, the WisdomTree Biorevolution UCITS ETF (Ticker: WDNA) is worth taking a deeper look at.

1 Source: https://www.youtube.com/watch?v=8oVRYQe2bX8

2 Source: Nathan-Kazis, Josh. "Moderna Reports More Promising Data on Its Cancer Treatment. The Stock Jumps." Barron's. December 14, 2023.

3 Source: https://www.wisdomtree.eu/en-gb/blog/2023-12-13/is-it-time-for-biotech

4 Source: https://s29.q4cdn.com/435878511/files/doc_earnings/2023/q3/presentation/Moderna-3Q23-Earnings-Presentation-Final.pdf

Related blogs

+ Is it Time for Biotech?

Important Risks Related to this Article

IMPORTANT INFORMATION

Marketing communications issued in the European Economic Area ("EEA"): This document has been issued and approved by WisdomTree Ireland Limited, which is authorised and regulated by the Central Bank of Ireland.

Marketing communications issued in jurisdictions outside of the EEA: This document has been issued and approved by WisdomTree UK Limited, which is authorised and regulated by the United Kingdom Financial Conduct Authority.

WisdomTree Ireland Limited and WisdomTree UK Limited are each referred to as "WisdomTree" (as applicable). Our Conflicts of Interest Policy and Inventory are available on request.

For professional clients only. Past performance is not a reliable indicator of future performance. Any historical performance included in this document may be based on back testing. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of such strategy would have been. Back tested performance is purely hypothetical and is provided in this document solely for informational purposes. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance. The value of any investment may be affected by exchange rate movements. Any decision to invest should be based on the information contained in the appropriate prospectus and affer seeking independent investment, tax and legal advice. These products may not be available in your market or suitable for you. The content of this document does not constitute investment advice nor an offer for sale nor a solicitation of an offer to buy any product or make any investment.

An investment in exchange-traded products ("ETPs") is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely. ETPs involve numerous risks including among others, general market risks relating to the relevant underlying index, credit risks on the provider of index swaps utilised in the ETP, exchange rate risks, interest rate risks, inflationary risks, liquidity risks and legal and regulatory risks.

The information contained in this document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares in the United States or any province or territory thereof, where none of the issuers or their products are authorised or registered for distribution and where no prospectus of any of the issuers has been filed with any securities commission or regulatory authority. No document or information in this document should be taken, transmitted or distributed (directly or indirectly) into the United States. None of the issuers, nor any securities issued by them, have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes.

This document may contain independent market commentary prepared by WisdomTree based on publicly available information. Although WisdomTree endeavours to ensure the accuracy of the content in this

document, WisdomTree does not warrant or guarantee its accuracy or correctness. Any third party data providers used to source the information in this document make no warranties or representation of any kind relating to such data. Where WisdomTree has expressed its own opinions related to product or market activity, these views may change. Neither WisdomTree, nor any affiliate, nor any of their respective officers, directors, partners, or employees accepts any liability whatsoever for any direct or consequential loss arising from any use of this document or its contents.

This document may contain forward looking statements including statements regarding our belief or current expectations with regards to the performance of certain assets classes and/or sectors. Forward looking statements are subject to certain risks, uncertainties and assumptions. There can be no assurance that such statements will be accurate and actual results could differ materially from those anticipated in such statements. WisdomTree strongly recommends that you do not place undue reliance on these forward-looking statements.

The products discussed in this document are issued by WisdomTree Issuer ICAV (“WT Issuer”). WT Issuer is an umbrella investment company with variable capital having segregated liability between its funds organised under the laws of Ireland as an Irish Collective Asset-management Vehicle and authorised by the Central Bank of Ireland (“CBI”). WT Issuer is organised as an Undertaking for Collective Investment in Transferable Securities (“UCITS”) under the laws of Ireland and shall issue a separate class of shares ("Shares") representing each fund. Investors should read the prospectus of WT Issuer (“WT

Prospectus”) before investing and should refer to the section of the WT Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in the Shares.

Notice to Investors in Switzerland

Qualified Investors This document constitutes an advertisement of the financial product(s) mentioned herein. The prospectus **and the key investor information documents (KIID) are available from WisdomTree's website:** https://www.wisdomtree.eu/en- ch/resource-library/prospectus-and-regulatory-reports Some of the sub-funds referred to in this document may not have not been registered with the Swiss Financial Market Supervisory Authority (“FINMA”). In Switzerland, such sub-funds that have not been registered with FINMA shall be distributed exclusively to qualified investors, as defined in the Swiss Federal Act on Collective Investment Schemes or its implementing ordinance (each, as amended from time to time). The representative and paying agent of the sub-funds in Switzerland is Société Générale Paris, Zurich Branch, Talacker 50, PO Box 5070, 8021 Zurich, Switzerland. The prospectus, the key investor information documents (KIID), the articles of association and the annual and semi-annual reports of the sub-funds are available free of charge from the representative and paying agent. As regards distribution in Switzerland, the place of jurisdiction and performance is at the registered seat of the representative and paying agent.

For Investors in France

The information in this document is intended exclusively for professional investors (as defined under the MiFID) investing for their own account and this material may not in any way be distributed to the public.

The distribution of the Prospectus and the offering, sale and delivery of Shares in other jurisdictions may be restricted by law. WT Issuer is a UCITS governed by Irish legislation, and approved by the Financial Regulatory as UCITS compliant with European regulations although may not have to comply with the same rules as those applicable to a similar product approved in France. The Fund has been registered for marketing in France by the Financial Markets Authority (Autorité des Marchés Financiers)

and may be distributed to investors in France. Copies of all documents (i.e. the Prospectus, the Key Investor Information Document, any supplements or addenda thereto, the latest annual reports and the memorandum of incorporation and articles of association) are available in France, free of charge at the French centralizing agent, Societe Generale at 29, Boulevard Haussmann, 75009, Paris, France. Any subscription for Shares of the Fund will be made on the basis of the terms of the prospectus and any supplements or addenda thereto.

For Investors in Malta

This document does not constitute or form part of any offer or invitation to the public to subscribe for or purchase shares in the Fund and shall not be construed as such and no person other than the person to whom this document has been addressed or delivered shall be eligible to subscribe for or purchase shares in the Fund. Shares in the Fund will not in any event be marketed to the public in Malta without the prior authorisation of the Maltese Financial Services Authority.

For Investors in Monaco

This communication is only intended for duly registered banks and/or licensed portfolio management companies in Monaco. This communication must not be sent to the public in Monaco.